BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10353444)

  • 1. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study.
    Löhr M; Bago ZT; Bergmeister H; Ceijna M; Freund M; Gelbmann W; Günzburg WH; Jesnowski R; Hain J; Hauenstein K; Henninger W; Hoffmeyer A; Karle P; Kröger JC; Kundt G; Liebe S; Losert U; Müller P; Probst A; Püschel K; Renner M; Renz R; Saller R; Salmons B; Walter I
    J Mol Med (Berl); 1999 Apr; 77(4):393-8. PubMed ID: 10353444
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gene therapy of pancreatic cancer with microencapsulated CYP2B1-expressing cells].
    Löhr M; Faulmann G; Hummel F; Singer MV
    Onkologie; 2001 Sep; 24 Suppl 5():60-4. PubMed ID: 11600815
    [No Abstract]   [Full Text] [Related]  

  • 3. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century.
    Löhr M; Hummel F; Faulmann G; Ringel J; Saller R; Hain J; Günzburg WH; Salmons B
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S21-4. PubMed ID: 12042985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.
    Löhr M; Hoffmeyer A; Kröger J; Freund M; Hain J; Holle A; Karle P; Knöfel WT; Liebe S; Müller P; Nizze H; Renner M; Saller RM; Wagner T; Hauenstein K; Günzburg WH; Salmons B
    Lancet; 2001 May; 357(9268):1591-2. PubMed ID: 11377651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide.
    Samel S; Keese M; Lux A; Jesnowski R; Prosst R; Saller R; Hafner M; Sturm J; Post S; Löhr M
    Cancer Gene Ther; 2006 Jan; 13(1):65-73. PubMed ID: 16096652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-arterial instillation of microencapsulated, Ifosfamide-activating cells in the pig pancreas for chemotherapeutic targeting.
    Kröger JC; Benz S; Hoffmeyer A; Bago Z; Bergmeister H; Günzburg WH; Karle P; Klöppel G; Losert U; Müller P; Nizze H; Obermaier R; Probst A; Renner M; Saller R; Salmons B; Schwendenwein I; von Rombs K; Wiessner R; Wagner T; Hauenstein K; Löhr M
    Pancreatology; 2003; 3(1):55-63. PubMed ID: 12649565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 reductase dependent inhibition of cytochrome P450 2B1 activity: Implications for gene directed enzyme prodrug therapy.
    Lengler J; Omann M; Düvier D; Holzmüller H; Gregor W; Salmons B; Günzburg WH; Renner M
    Biochem Pharmacol; 2006 Sep; 72(7):893-901. PubMed ID: 16887103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.
    Ryschich E; Jesnowski R; Ringel J; Harms W; Fabian OV; Saller R; Schrewe M; Engel A; Schmidt J; Löhr M
    Int J Cancer; 2005 Feb; 113(4):649-53. PubMed ID: 15455374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
    Karle P; Renner M; Salmons B; Günzburg WH
    Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy.
    Karle P; Müller P; Renz R; Jesnowski R; Saller R; von Rombs K; Nizze H; Liebe S; Günzburg WH; Salmons B; Löhr M
    Adv Exp Med Biol; 1998; 451():97-106. PubMed ID: 10026857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
    Müller P; Jesnowski R; Karle P; Renz R; Saller R; Stein H; Püschel K; von Rombs K; Nizze H; Liebe S; Wagner T; Günzburg WH; Salmons B; Löhr M
    Ann N Y Acad Sci; 1999 Jun; 880():337-51. PubMed ID: 10415878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450.
    Löhr M; Müller P; Karle P; Stange J; Mitzner S; Jesnowski R; Nizze H; Nebe B; Liebe S; Salmons B; Günzburg WH
    Gene Ther; 1998 Aug; 5(8):1070-8. PubMed ID: 10326030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy.
    Günzburg WH; Karle P; Renz R; Salmons B; Renner M
    Ann N Y Acad Sci; 1999 Jun; 880():326-36. PubMed ID: 10415877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.
    Salmons B; Löhr M; Günzburg WH
    J Gastroenterol; 2003 Mar; 38 Suppl 15():78-84. PubMed ID: 12698877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs.
    Philip PA; Ali-Sadat S; Doehmer J; Kocarek T; Akhtar A; Lu H; Chan KK
    Cancer Chemother Pharmacol; 1999; 43(1):59-67. PubMed ID: 9923542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L; Waxman DJ
    Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.
    Binder S; Lewis AL; Löhr JM; Keese M
    World J Gastroenterol; 2013 Nov; 19(43):7586-93. PubMed ID: 24282349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel clinical strategies for the treatment of pancreatic carcinoma.
    Günzburg WH; Salmons B
    Trends Mol Med; 2001 Jan; 7(1):30-7. PubMed ID: 11427987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
    Samel S; Löhr M
    Cancer Treat Res; 2007; 134():469-82. PubMed ID: 17633075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.